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Abstract
Background: Although some studies indicate that bipolar disorder causes high health care resources consumption, no 
study is available addressing a cost estimation of bipolar disorder in Spain. The aim of this observational study was to 
evaluate healthcare resource utilization and the associated direct cost in patients with manic episodes in the Spanish 
setting.
Methods: Retrospective descriptive study was carried out in a consecutive sample of patients with a DSM-IV diagnosis 
of bipolar type I disorder with or without psychotic symptoms, aged 18 years or older, and who were having an active 
manic episode at the time of inclusion. Information regarding the current manic episode was collected retrospectively 
from the medical record and patient interview.
Results: Seven hundred and eighty-four evaluable patients, recruited by 182 psychiatrists, were included in the study. 
The direct cost associated with healthcare resource utilization during the manic episode was high, with a mean cost of 
nearly €4,500 per patient, of which approximately 55% corresponded to the cost of hospitalization, 30% to the cost of 
psychopharmacological treatment and 10% to the cost of specialized care.
Conclusions: Our results show the high cost of management of the patient with a manic episode, which is mainly due 
to hospitalizations. In this regard, any intervention on the management of the manic patient that could reduce the 
need for hospitalization would have a significant impact on the costs of the disease.
Background
Bipolar disorder is a mood disorder characterized by
extreme mood swings that cause recurrent episodes of
mania or hypomania and depression [1]. Historically, it
was called "circular madness" and "manic-depressive psy-
chosis". According to DSM-IV-TR, two major categories
of bipolar disorder exist: bipolar I disorder, in which
patients have had at least one episode of mania, some
have had previous depressive episodes, and most will
have subsequent manic, depressive, hypomanic or mixed
episodes; and bipolar II disorder, in which patients
exhibit or have a history of major depressive episodes and
hypomanic, but not manic, episodes [2].
In Europe, the estimated annual prevalence of bipolar
disorder ranges from 0.2 to 1.1% with a median of 0.9%,
i.e., 2.4 million people are affected by the disorder [3]. In
Spain, using data on lithium consumption, the prevalence
of bipolar I disorder has been estimated at 70 cases per
100,000 inhabitants [4], a figure that, because of the
method used, underestimates the true prevalence of the
disorder. Bipolar disorder is not only common, but is also
an important cause of disability; it exhibits frequent psy-
chiatric comorbidity, is associated with a high frequency
of suicide, has a large impact on the functioning and well-
being of the individual, and places a considerable eco-
nomic burden on the individual and society [5-13].
According to the World Health Organization, bipolar
disorder is the sixth leading cause of disability worldwide
among persons aged 15 to 44 years [5], and the third
among mental illnesses (after major depression and
schizophrenia). The data provided by this organization in
2005 attributed more than thirty percent of all years lived
with disability to neuropsychiatric disorders [6]. In addi-
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tion, patients with bipolar disorder have high psychiatric
and medical comorbidity; in studies conducted in
Europe, nearly all patients with bipolar I disorder had a
history of having suffered another axis I disorder in their
lifetime, more than two thirds had a history of one or
more anxiety disorders and 70% had a history of a sub-
stance abuse disorder [7]. The lifelong risk of suicide in
bipolar disorder is up to 20 times higher than in the gen-
eral population [8-10]. Several studies have shown that
even in less symptomatic patients (i.e. sub-threshold
symptoms present), bipolar disorder causes a significant
impairment of the functioning and well-being of the indi-
vidual [11-13].
The studies conducted to date have identified high
resource utilization and costs in bipolar disorders that
were the highest among psychiatric disorders [14,15]. A
prevalence cost study conducted in the USA estimated
that the total cost of bipolar disorder in 1991 was $45 bil-
lion [16]. Another study on incident cases in 1998 esti-
mated the lifetime cost of bipolar disorder at $24 billion
[17]. Another study has recently been published in which
the treatment costs of bipolar disorder in the USA in
2002 were estimated. The results were $12,797 and
$6,581 for the mean charge and reimbursement per
patient-year, respectively. In this study, 33% of the treat-
m e n t  c o s t  w a s  a t t r i b u t e d  t o  b i p o l a r  d i s o r d e r  a n d  t h e
remaining 67% to associated comorbidity [18]. In Austra-
lia, the excess cost of bipolar disorder in 2004 was esti-
mated at US$4-5 billion [19].
In Europe, only four studies have assessed the cost of
bipolar disorder [15]: two in France focusing on manic
episodes [20,21], one in the Netherlands [22] and another
in the United Kingdom [23], these last two focusing on
bipolar disorder. The results differ greatly between the
European and US studies; in the UK study, direct costs
were estimated at approximately €285 million, compared
to the equivalent of €3 billion in the USA [16]. The differ-
ences between the studies in Europe are also large with,
for instance, direct costs that range from €700 to €24,000
per patient depending on the study [20-23]. These differ-
ences reflect differences in the management of the dis-
ease (mostly rates and duration of hospitalization) as well
as the different perspectives in research question and
methodologies.
No study is available on the costs of bipolar disorder in
Spain. Very recently published data from a subsample of a
pan-European study indicate that bipolar disorder causes
high healthcare resource utilization in the Spanish set-
ting, although no cost estimate was provided [24]. In
another estimate of the cost of disorders of the brain in
E u r o pe  [ 2 5 ] ,  i t  was  s h o wn  t h a t  b i po l a r  d is o r d e r  is  t h e
mental disorder generating the highest costs in Spain
(5,807 €PPP 2004 (Purchasing power parity) per patient
versus 5,082 for schizophrenia and 3,445 for depression).
The aim of the present study was to evaluate healthcare
resource utilization and the associated direct cost in
patients with manic episodes in our setting.
Methods
An observational study with retrospective data collection
was carried out in a sample formed by consecutive
patients with a DSM-IV diagnosis of bipolar type I disor-
der with or without psychotic symptoms visiting psychia-
trist outpatient offices in Spain. The selected patients
were aged 18 years or older, were having an active manic
episode at the time of inclusion and were in contact with
specialized care (public or private) for this reason in
Spain during the reference period of April 2005 to March
2006.
Patients could be included at any time during the
course of a manic episode, and information regarding the
period between the onset of symptoms of that episode to
the time of inclusion was collected retrospectively at the
recruitment moment. A second phase of data collection
was performed when the episode had ended. A maximun
period of four months was defined in the protocol as suf-
ficient for complete remission of the episode, and
patients with no remission at four months were no longer
followed. The study was carried out under real-world
clinical practice conditions in an outpatient setting and
information was collected in a case report form designed
for this purpose.
The study was evaluated and approved by the ethics
committee of Hospital Clínico San Carlos de Madrid and
carried out in accordance with the ethical recommenda-
tions for clinical research contained in the Declaration of
Helsinki and Good Clinical Practice guidelines. Written
informed consent was obtained from all patients prior to
their inclusion in the study.
Information was collected on each patient characteris-
tics (sociodemographics, personal and family medical
history), disease characteristics (duration of compatible
symptoms, diagnosis, previous episodes) and current epi-
sode characteristics. All healthcare resources consumed
during the current episode (drugs, outpatient and hospi-
tal care) were recorded using the medical history and
patient interview as sources of data. The evaluator made
a judgment about the relationship of each resource con-
sumed with the patient's disease. Information was also
collected on the existence of any legal or judicial prob-
lems during the manic episode, although their costs were
not estimated.
The unit costs assigned to the healthcare resource utili-
zation recorded for each patient were obtained from a
healthcare unit costs database [26]. These unit costs were
then updated to the year 2007 according to the corre-
sponding inflation rate, 12.5% [27]. In addition, the costs
of psychologist visits and group psychotherapy wereTafalla et al. BMC Psychiatry 2010, 10:31
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obtained by calculating the average value of the fee lists
published by several official psychologists' associations
on the minimum cost of a patient visit. Finally, the cost of
prescription drugs was obtained from the retail price of
each individual drug including VAT published by the
General Board of the Spanish Association of Official
Pharmacists [28]. The cost per mg was then calculated to
assign the actual cost of the drug to the dose prescribed
and treatment duration in each patient. A list of all costs,
expressed in 2007 Euros, is shown in Table 1.
Statistical analysis was performed by describing demo-
graphic variables, patient disease and resource utilization.
Quantitative variables (e.g., age, disease duration, abso-
lute frequency of resource utilization) were described by
their mean values and standard deviations. Categorical
variables (e.g., gender, comorbidity, presence of a specific
number of hospitalizations or other resource utilization)
were described by their absolute and relative frequencies.
In addition, to evaluate how sociodemographic or clini-
cal characteristics affected resource utilization, explor-
atory bivariate analyses were used to compare resource
utilization according to the values that could be taken by
the different variables. To evaluate the significance of the
difference, Student's t test or the Wilcoxon signed rank
test was used for quantitative variables and the chi-
squared test for Fisher's exact test for categorical vari-
ables. All statistical tests were two-tailed and were con-
sidered significant if p < 0.05. Due to the exploratory
nature of these analyses, no correction for multiple com-
parisons was used.
Results
Nine hundred and ten patients, evaluated by 182 psychia-
trists, were included in the study. Of these, 126 patients'
data were considered non-evaluable because of missing
or inconsistent values and then excluded from the data
base.
Demographic characteristics of evaluable patients are
shown in Table 2. Most patients lived with their partner
and were employed, although a substantial percentage
(21.3%) were on disability leave. Most of the sample lived
in small urban areas with populations between 10,000
and 100,000 or medium-sized urban areas with popula-
tions between 100,000 and 1,000,000.
Clinical characteristics of the patients are described in
Table 3. The first professional consulted by patients for
the initial episode was the psychiatrist in the majority of
cases, and this episode required hospital admission in
23.6% of cases. Only 4.1% of patients were newly diag-
nosed. In the twelve months prior to the current episode,
Table 1: Unit cost per healthcare resource used and source of estimate
Resource Source of estimate Cost (€, 2007)
Hospitalization
Psychiatric hospital stay/day Soikos (2004) & INE (2007) 240.27
Primary care
Primary care physician visit Soikos (2004) & INE (2007) 15.67
Community-based visiting nurse 
service
Soikos (2004) & INE (2007) 15.65
Lithium determination Soikos (2004) & INE (2007) 9.02
Group psychotherapy Official Psychologist Associations of 
Cataluña, Castilla la Mancha, Cantabria, Las 
Palmas, Barcelona
24.86
Outpatient emergency dept. visit Soikos (2004) & INE (2007) 110.94
Specialized care
Psychiatrist visit Soikos (2004) & INE (2007) 39.99
Nonpyschiatric specialist visit Soikos (2004) & INE (2007) 79.46
Psychologist visit Official Psychologist Associations of 
Cataluña, Castilla la Mancha, Cantabria, Las 
Palmas, Barcelona
50
Hospital emergency dept. visit Soikos (2004) & INE (2007) 120.21Tafalla et al. BMC Psychiatry 2010, 10:31
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Table 2: Demographic characteristics
Characteristic N
Gender, n (%) 761
Male 343 (45.2)
Female 418 (54.8)
Age, years, mean ± SD
Total 761 43.5 ± 12.1
Male 343 41.9 ± 12.2
Female 418 44.8 ± 11.8
Educational status, n (%) 784
No studies 73 (9.3)
Primary school 340 (43.4)
Secondary school 256 (32.6)
University 115 (14.7)
Marital status, n (%) 762
Married or cohabiting 337 (44.2)
Previously married 136 (17.9)
Never married 289 (37.9)
Employment status, n (%) 762
Paid employment 202 (26.5)
Unemployed 81 (10.6)
Retired 81 (10.6)
Housewife 130 (17.1)
Student 24 (3.1)
Sick leave 66 (8.7)
Work disability 162 (21.3)
Other 16 (2.1)
Area of residence, n (%) 760
Rural 156 (20.5)
Small urban 259 (34.1)
Medium urban 255 (33.6)
Large urban 90 (11.8)
Living situation, n (%) 779
Lives alone 98 (12.6)
Lives with someone 681 (87.4)
SD: standard deviation; N: number of evaluable casesTafalla et al. BMC Psychiatry 2010, 10:31
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Table 3: Clinical characteristics
Characteristic N
First episode
Age at onset of BD, years, mean ± SD 737 29.0 ± 10.3
First manic/mixed episode, n (%) 748 479 (64.0)
Time since first episode at diagnosis, 
years, mean ± SD
734 2.4 ± 5.6
Type of first contact with healthcare 
sector, n (%)
Psychiatrist 300 (41.5)
Hospitalization 171 (23.6)
Primary care 140 (19.3)
Emergency department 724 72 (9.9)
Other 41 (5.7)
Current episode
Total duration, days, mean ± SD 708 76.4 ± 43.0
Clinical status prior to current 
episode, n (%)
741
Euthymia 567 (76.5)
Depression 174 (23.5)
Suicide 744
Presence of previous attempts, n (%) 209 (28.1)
Psychiatric comorbidity1, n (%) 749
Any concomitant psychiatric disorder 410 (54.7)
Substance abuse/dependence 
disorder
200 (26.7)
Anxiety disorders 119 (15.9)
Personality disorder 107 (14.3)
Impulse control disorder 65 (8.7)
Eating behavior disorder 36 (4.8)
Other disorders 28 (3.7)
High adherence to previous visits 
schedule, n (%)
743 513 (69.0)
High adherence to previous treatment, n 
(%)
744 458 (61.6)
1Patients could have more than one disorder
SD: standard deviation; N: number of evaluable cases; BD: bipolar disorderTafalla et al. BMC Psychiatry 2010, 10:31
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only 32.8% of patients had been free from symptoms. In
this period, 30.9% of patients had had one episode of
mood disorder and 20.2% two episodes. Of the total sam-
ple, 6.5% met the criteria for rapid cycling (four or more
episodes a year). Up to 28.1% had a previous suicide
attempt. Less than 10% of patients had never been hospi-
talized from the onset of their disease to the time of
inclusion in the study, and 25.6% had been admitted more
than 5 times during this period. From the physician's per-
spective, up to 31% of patients had shown low adherence
to the previous visit schedule, and up to 38.4% had shown
low adherence to previously prescribed treatments.
Mean total duration of the current manic episode was
76.4 days (SD: 43). Prior to the current episode, 76.5% of
patients were in an euthymic state and up to 23.5% were
in a depressed mood state.
The information on resource utilization is shown in
Tables 4. Half of the sample studied required hospitaliza-
tion, which was in a general hospital in 71.8% of the cases.
The mean length of hospital stay was 22.9 days (SD: 15.5),
and bipolar disorder was the primary reason for admis-
sion in 93% of the cases. The mean number of visits to the
primary care physician during the episode was 1.9 and 1.6
to the community-based nurse service. The specialist was
visited a mean of 5.7 times during the episode. Patients
with four or more episodes in the previous year had more
lithium determinations (1.1 vs. 2.7; p = 0.0003), and made
more visits to outpatient emergency services (0.4 vs. 1.4;
p < 0.0001) due to their current manic episode. Patients
who had never been married (p = 0.424), were from a
rural setting (p = 0.0048) and had longer disease duration
(p for trend = 0.0137) were hospitalized more frequently.
Patients who lived alone made more visits to the psychia-
trist (8.6 vs. 5.3 times, p = 0.0032). The presence of a his-
tory of suicide attempt was associated with a higher
number of visits to the psychologist (1.1 vs. 0.6, p = 0.02),
non-psychiatrist specialist (0.6 vs. 0.1, p < 0.0001) and
hospital emergency department (1.6 vs. 0.8, p = 0.0005).
Finally, the absence of psychiatric comorbidity was asso-
ciated with a higher number of visits to the psychologist.
The pharmacological treatment received by patients over
the course of their episode consisted of antipsychotics,
mood stabilizers and anxiolytics with frequencies of
94.6%, 83.9% and 55.2%, respectively.
The mean total cost of the manic episode in the sample
studied was €4,345. Of this cost, 56% corresponds to hos-
pitalization, 10% to specialist care (mainly from psychia-
trist visits, with a mean of 6), 14% to antipsychotics and
15% to other psychoactive drugs (Figure 1). The direct
costs associated with the resources used are shown in
Table 5.
Discussion
T h i s  n a t u r a l i s t i c  s t u d y  s h o w s  t h a t  m a n a g e m e n t  o f  a
manic episode in the Spanish setting is associated with
high healthcare resource utilization, particularly in terms
of hospitalization and specialized care in the form of fre-
quent psychiatrist visits. The direct cost associated with
healthcare resource utilization is high, with a mean cost
of nearly €4,500 per patient, of which approximately 55%
corresponds to the cost of hospitalization, 30% to the cost
of psychopharmacological treatment and 10% to the cost
of specialized care.
To our knowledge, this is the first study of these charac-
teristics conducted in Spain, so it is not possible for us to
put our results in perspective within our setting. The
Table 4: Resource utilization in a cohort of patients with bipolar disorder who had a manic episode: hospitalizations
Characteristics N
Required hospitalization, n (%) 782 391 (50)
Days of hospitalization1, mean ± SD 383 22.9 ± 15.5
Cause of hospitalization1, n (%) 389
Current manic episode2 362 (93.0)
Psychiatric comorbidity 14 (3.6)
Other causes 13 (3.4)
Type of hospital1, n (%) 386
Monographic 109 (28.2)
General 277 (71.8)
1Calculated over the number of evaluable patients who required hospitalization
2Includes 4 cases in which the reason for hospitalization was attributed to both the manic episode and the comorbidity
SD: standard deviation; N: number of evaluable casesTafalla et al. BMC Psychiatry 2010, 10:31
http://www.biomedcentral.com/1471-244X/10/31
Page 7 of 10
results obtained in the Spanish subsample of 312 patients
within the pan-European EMBLEM study, a long-term
observational study of acute patients undergoing treat-
ment for mania, have recently been published [24].
Although this subanalysis of the EMBLEM study is very
limited with regard to healthcare resource utilization, it
does appear to indicate a significant utilization of some
healthcare services by these patients in the year prior to
inclusion in the study. However, the methodology used,
which was limited to the use of a small number of health-
care resources (i.e., hospitalizations and outpatient psy-
chiatric visits) in the year prior to the episode, prevents
comparison with our results since they would not corre-
spond to the resource utilization associated with a manic
episode.
Very similar to our study in terms of objectives was a
study conducted in France that evaluated the direct cost
of treatment of manic episodes during a three-month
period following hospitalization [20]. The cost, in 1999
values, was much higher than in our study, €22,297 per
episode, and 98% corresponded to hospitalization [20]. At
least in Europe, the cost of hospitalization is the most sig-
nificant portion of the direct costs of bipolar disorder
[29], and furthermore, the largest part of these costs of
hospitalization is attributable to bipolar I disorder [30].
Therefore, as indicated by the results of Olié & Lévy's [20]
and our study, hospitalization is key in the cost of man-
agement of patients with bipolar I disorder and, more
specifically, of the manic episode. Irrespective of possible
differences in the unit cost per resource, there are several
important differences related to hospitalization in the
French study that could explain the differences in the cost
of the manic episode between the two studies. Only hos-
pitalized patients were included in the French study,
whereas in our study, more than 50% of patients were not
hospitalized. Furthermore, the mean duration of hospi-
talization was 36 days in the French study versus 23 days
in our study, and follow-up was for 90 days in the French
study versus a mean duration of the episode of 76 days in
our study. Although these differences could be attributed
to variability in medical practices and resource availabil-
ity in the two countries, it should be noted that differen-
tial diagnosis between mania and hypomania in DSM-IV-
TR includes use of hospital resources as a diagnostic cri-
terion, which constitutes a peculiarity within the field of
medical nosology. In any case, the contribution of hospi-
talization to the cost of manic episodes is very significant,
independent of the geographical area. Thus, costs of hos-
pitalization also account for the largest proportion of the
total costs of bipolar disorder in Australia (70% of the
excess healthcare costs of bipolar disorder are due to hos-
pital admissions) [19] and in the United States, where
36% of the annual cost of patients with bipolar I disorder
is due to hospitalization for privately insured patients
[31].
After hospitalization, the next greatest cost in our study
is the cost of psychopharmacological treatment (30% of
total cost). The cost of antipsychotic treatment represents
50% of this pooled cost. The pattern of psychopharmaco-
logical treatment in our study, with use of antipsychotics
and mood stabilizers in 95% and 84% of patients, is prac-
tically superimposable on that described in the previously
m e n t i o n e d  s t u d y  o f  O l i é  &  L é v y  [ 2 0 ]  c o n d u c t e d  i n
France. However, the cost of medication in the latter
study was a minimal proportion (0.3%) of the cost of
treatment in the three months following the manic epi-
sode. This was probably due to the disproportionate (for
the previously explained reasons) importance of hospital-
ization in this study and the predominant use of conven-
tional antipsychotics. However, in the study of privately
insured patients in the United States [31], the cost of psy-
chopharmacological treatment was 13% of the total cost.
Our study has a number of important limitations. First,
convenience sampling was used, so this sample is not rep-
resentative of patients with a manic episode in Spain.
While it is true that the overall demographic and clinical
characteristics of the patients in our study are very simi-
lar to those of the Spanish sample in the EMBLEM study
[24], patients from the rural setting may be underrepre-
sented in both studies.
The problem of lack of representativeness affects most
cost studies carried out using a "bottom-up" methodol-
ogy (activity-based costing method that assess the
amount of each resource that is used to produce an indi-
vidual healthcare service and then assigns costs accord-
ingly to generate aggregate costs for a healthcare system).
The main advantage is being able to trace the contribu-
tion of each element of an organization to the cost of an
individual healthcare service, which allows for better cost
management when is particularly relevant for assessing
the cost of individual services within complex integrated
healthcare systems, as the Spanish one. Additionally, the
type of information obtained through a "bottom-up" is
Figure 1 Percent distribution of direct costs associated with the 
management of a patient with a manic episode (N = 708).
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very relevant for its inclusion in cost-effectiveness model-
ing studies using combined or cross-national synthesis
designs [32]. On the other side, a "top-down" approach
(using relative value units, hospitals days, or some other
metric to assign total costs for a healthcare system to
individual services) could be useful as well in order to
assess local cost variation. From our point of view, an uti-
lization of both methods could be advantageous because
different methods can serve different purposes, and
finally are complementary [33].
The study protocol did not define a standardized
method for patient diagnosis, but followed psychiatrist
opinion, and this could affect the validity of diagnosis,
although we presume that the case of mania could be not
as affected as other mental diagnoses. Moreover, for pub-
lic health decisions the relevant cost of a disease comes
from the population considered by the specialists as suf-
fering from the disease.
Also, due to the descriptive retrospective study design,
no information can be provided on some predictors of
higher cost, such as treatment adherence or persistence
on treatment. It has been shown that a better adherence
associates with a lower cost in the long term treatment
[34].
With regard to the method used for cost allocation, it is
important to point out two limitations in our study. First,
Table 5: Direct costs associated with the management of a patient with a manic episode (N = 708)
Resource Number of times during 
manic episode
Cost (€, 2007)
Mean ± SD Mean ± SD 95% CI
Hospitalization
Psychiatric hospital stay/day 2462 ± 3424 2210 - 2715
Primary care
Primary care physician visit 1.9 ± 6.0 31 ± 97 24 - 39
Nurse visit 1.6 ± 4.3 21 ± 56 17 - 25
Lithium determination 1.3 ± 3.1 12 ± 29 10 - 14
Group psychotherapy 0.6 ± 10.8 25 ± 454 0 - 58
Outpatient emergency dept. 
visit
0.6 ± 1.8 68 ± 213 52 - 84
Specialized care
Psychiatrist visit 5.7 ± 10.3 258 ± 429 227-290
Nonpsychiatric specialist visit 0.3 ± 1.4 22 ± 113 14 - 30
Psychologist visit 0.8 ± 2.4 39 ± 124 30 - 48
Hospital emergency dept. visit 1.0 ± 2.8 124 ± 352 98 - 150
Pharmacological treatment
Antipsychotics 751 (94.6) 617 ± 656 569 - 665
Other psychoactive drugs1 Range from 52 
(anticholinergics) to 666 
(mood stabilizers
666 ± 679 616 - 716
Total cost 4345 ± 4019 4048 - 4641
SD: standard deviation; CI: confidence interval; 1Other psychoactive drugs: Includes the cost associated with mood stabilizers, anxiolytics/
hypnotics, antidepressants and anticholinergics.Tafalla et al. BMC Psychiatry 2010, 10:31
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the healthcare costs database used, SOIKOS, has been
the standard in Spain for several years. This private data-
base is based on the information gathered from govern-
ment agency publications, published studies and
literature reviews, among others. Its very nature means
that the costs provided have not been sufficiently verified
or have rapidly become outdated. Second, adjustment of
these costs according to inflation is a method that has
been questioned on some occasions, a factor that should
also be taken into account. Ideally, to overcome these lim-
itations, a single nationwide database, mainly related to
public costs as Spain has a public health care system
funded by public taxes, would be needed to perform a
cost allocation closer to the reality of our healthcare sys-
tem.
On the other hand, it should be stressed that a more
conservative perspective was adopted in this study, and
only direct costs were analyzed. No costs were allocated
to disease associated mortality, lost productivity, use of
the legal or penal system or the associated family burden,
in spite of the relative importance of these costs. Regard-
ing the impact of legal problems, reports about the
importance of mental health problems in the prison and
jail inmates in the USA, estimate that up to 50% of
inmates with mental problems report symptoms of mania
[35].
Of the estimated $45 billion total cost of bipolar disor-
der in the United States in 1991 [16], more than 80% was
due to indirect costs, a very similar proportion to that
described in another study in the Netherlands [22]. Simi-
larly, of the total excess cost of bipolar disorder in Austra-
lia, the largest proportion (85%) was due to individual
expenses; 60% of these were due to absenteeism from
work and 39% to "presenteeism" (present at work but not
functioning efficiently). This large impact on productivity
extends beyond the manic episode. In a prospective study
six months after discharge that evaluated patients who
had been hospitalized after a manic episode, even though
80% were practically symptom free, only 43% were
employed and only 21% were working at their expected
level of employment [12].
The work disability rate found in our sample is similar
to that reported in a study on the employment status of
persons with severe chronic mental illnesses based on the
national survey on disability conducted in 1999 (20.36%)
[36]. However, the employment rate of the persons with
mania included in our study was lower than the employ-
ment rate of persons with mental disorders reported in
the ESEMeD study in Spain (36.7%) [37]. Furthermore,
access to sheltered employment conditions is consider-
ably lower in patients with bipolar disorder than in other
severe mental disorders. In Catalonia, only 7% of persons
in sheltered employment had bipolar disorder, compared
to the 62% with schizophrenia or 8% with borderline per-
sonality disorder (MHEEN-II, 2007). These data indicate
that the employment status of persons with bipolar type I
disorder requires a specific approach in Spain.
Although it has been pointed that other health eco-
nomic appraisals can help more policy makers determine
the maximum societal benefit that can be achieved, given
a finite amount of resources [38], the cost of illness stud-
ies are still useful for both clinicians and health authori-
ties to better understand the main sources of cost and
identify those aspects that can be subject of interventions
and whose efficiency can be analyzed.
Conclusions
Our study is the first to study resource utilization and
costs associated with manic episodes in Spain using a
bottom-up approach. Like other studies conducted in
Europe and elsewhere, it shows the high cost of manage-
ment of the patient with a manic episode, which is mainly
due to hospitalizations. In this regard, any intervention in
the management of the manic patient that reduces the
need for hospitalization (e.g., improved preventive phar-
macological measures or measures that improve the fam-
ily or social support of the patient with bipolar disorder)
would have a significant impact on the costs of the dis-
ease.
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